Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

Item

http://www.wikidata.org/entity/Q39012785

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

@en

Adjuvant therapy following surgery in non-small cell lung cancer

@nl

type

Item

label

Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

@en

Adjuvant therapy following surgery in non-small cell lung cancer

@nl

prefLabel

Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

@en

Adjuvant therapy following surgery in non-small cell lung cancer

@nl

P1476

Adjuvant therapy following surgery in non-small cell lung cancer (NSCLC).

@en

P2093

Fumihiro Tanaka

http://www.w3.org/2001/XMLSchema#string

Kazue Yoneda

http://www.w3.org/2001/XMLSchema#string

P2860

Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data

Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a Laboratory Ancillary Study on an Eastern Cooperative Oncology Group Prospective Randomized Trial of Postoperative Adjuvant Therapy.

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

P304

25-37

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00595-015-1174-7

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25925615

http://www.w3.org/2001/XMLSchema#string